Wealthfront Advisers
CRSP icon

Wealthfront Advisers’s CRISPR Therapeutics CRSP Stock Holding History

Wealthfront Advisers’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$469K Buy
8,602
+57
+0.7% +$3K ﹤0.01% 885
2026
Q1 		$406K Sell
8,545
-602
-7% -$31.8K ﹤0.01% 877
2025
Q4 		$480K Buy
9,147
+1,688
+23% +$101K ﹤0.01% 827
2025
Q3 		$483K Buy
7,459
+1,456
+24% +$83.6K ﹤0.01% 827
2025
Q2 		$292K Buy
+6,003
New +$232K ﹤0.01% 869

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GP
GSK plc London $602M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Wealthfront Advisers's CRSP Position: Q2 2026 in Review

Wealthfront Advisers increased its CRISPR Therapeutics (CRSP) stake by 0.67% in Q2 2026, buying an estimated $3K and bringing the position to 8,602 shares worth $469K. The position accounts for ﹤0.01% of the portfolio, ranked #885.

Wealthfront Advisers first reported a position in CRSP in Q2 2025 and has held it in 5 quarters since. The position peaked at $483K in Q3 2025. 521 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

  • Wealthfront Advisers held 8,602 shares of CRISPR Therapeutics worth $469K as of Q2 2026.
  • Wealthfront Advisers bought 57 CRISPR Therapeutics shares in Q2 2026, an estimated $3K.
  • CRISPR Therapeutics made up ﹤0.01% of Wealthfront Advisers's portfolio in Q2 2026, its #885 holding.
  • Wealthfront Advisers first reported a position in CRISPR Therapeutics in Q2 2025 and has held it in 5 quarters since.
  • Wealthfront Advisers's CRISPR Therapeutics position peaked at $483K in Q3 2025.
  • 521 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on Wealthfront Advisers's 13F filing for Q2 2026, filed 7 Aug 2026.